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Abstract Elevation of the ocular pressure in the anterior cham- 
ber of the rat eye caused major iscbemie damage, manifested as 
changes in retinal morphology. The two most affected structures 
were the inner plexiform layer, which decreased in thickness by 
90%, and the number of ganglion cells, which decreased by 80%. 
Pretreatment of the animals with N'°-nitro-L-arginine, a nitric 
oxide (NOS) inhibitor, almost completely abolished the iscbemic 
damage. Administration of aminoguanidine, a NOS inhibitor se- 
lective for the inducible enzyme, partially abolished the ischemic 
damage. Moreover, administration of the NOS inhibitors 1 h 
after ischemia, also protected the retina from damage, suggesting 
that similarly acting drugs could be used clinically to limit is- 
chemic injury in humans. We conclude that NOS, and therefore 
NO, may be involved in the mechanism of iscbemic injury to the 
retina. 
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1. Introduction 
The involvement of NO in the ethiology of neurotoxicity, 
particularly that mediated by excitatory amino acids, is contro- 
versial. A number of laboratories reported that inhibition of 
NO formation had protective effects on neural cells in vivo 
[1-3]. Other reports suggest hat inhibition of NOS exacerbates 
ischemic injury, probably due to the effect of a decrease in NO 
on vascular beds [4-6]. Despite this controversy (for recent 
review see [7]), it is generally accepted that excessive generation 
of NO may contribute, or even directly cause damage to tissues 
after ischemic insult. 
The purpose of the present study was to investigate whether 
NO has a major role in the ethiology ofischemic damage in the 
rat retina, a relatively simple and well-established model of 
neural tissue. Our results suggest hat NO is indeed involved 
in a major way in the mechanism of ischemic damage. More- 
over, the ability to partially prevent the damage by post-is- 
chemic treatment of experimental nimals suggests that NOS 
inhibitors may be of use in limiting ischemic injury in humans. 
2. Materials and methods 
2.1. Induction of retinal ischemia 
Adult male albino rats, Spague-Dawley strain, 300400 g, were used 
throughout. The animals were housed at 12/12 h light/dark cycle, under 
controlled temperature (24°C) and with food and water ad libitum. The 
animals were anaesthesized with Equithesine (3 ml/kg) [8] and kept on 
a heated pad for the duration of anaesthesia with frequent monitoring 
of rectal temperature (37.0-37.2°C). Ischemia was achieved and the 
animals were treated essentially as described by Takahashi et al. [9]. 
*Corresponding author. Fax: (972) (3) 546 9580. 
Briefly, we instilled sterile saline i to the anterior chamber of one eye 
at 140 cm H20 pressure for 75 min, while the second eye served as 
non-ischemic control. Following ischemia, the animals were allowed to 
regain consciousness and kept for 7 days in a standard vivarium envi- 
ronment. On day 7, the animals were sacrificed by an injection of 
sodium penthotal and eyes were enucleated for histological examina- 
tion. 
2.2. NOS inhibitors adrnin&tration 
N%Nitro-L-arginine (NNA) or aminoguanidine (AG) were dissolved 
in water and titrated with HCI to insure complete dissolution of the 
drugs. The final pH of the solutions was 7.~7.5. Animals were injected 
intraperitoneally with either vehicle alone (vehicle controls) or with 5, 
25 or 50 mg/kg body weight of NNA and 25 or 50 mg/kg AG 1 h before 
the onset or 1 h after the termination of ischemia. 
2.3. Histology and morphometric studies 
The enucleated eyes were fixed in picric acid 2%, formaldehyde 40% 
in 95% ethanol for 48 h. Following fixation, the preparations were 
dehydrated by successive passages in 7(~100% ethanol and an addi- 
tional passage in 100% methanol. The preparation was then treated 
with 2 and 4% celloidine in 100% methanol, with 100% methyl salicylate 
and embedded in paraffin (Paraplast Plus, Sigma). The posterior part 
of the eye was sectioned saggitally at 7 ¢tm thickness through the optic 
nerve, mounted and stained with hematoxylline/eosine. For the estima- 
tion of the thickness of the inner etinal layer (IRL, between the internal 
limiting membrane and the interface of the outer plexiform and the 
outer nuclear layer) and the inner plexiform layer (IPL), measurements 
were performed with a calibrated reticle at x400 magnification atfour 
locations: adjacent to the optic disk (on both sides) and at the equator 
(on both sides). To estimate the number of retinal ganglion cells 
(RGCs), all cells from the equator to the optic disk (on each side) were 
counted. 
2.4. Statistics 
Four sections of each eye were used for measurements. 2-6 animals 
were used in each treatment group. Since there were virtually no differ- 
ences in the measurements of layer thicknesses in the four locations, the 
results were pooled from all the animals that were treated by the same 
protocol. Results are presented as mean + S.E. where n is the number 
of measurements performed and N denotes the number of eyes exam- 
ined for each condition. Student's t-test was used to estimate the signif- 
icance of the results. Differences between any two conditions were 
considered significant at P < 0.05. 
2.5. Materials 
NNA and AG were purchased from Sigma. All the other chemicals 
were of analytical grade. 
3. Results 
Elevation of the ocular pressure in the anterior chamber of 
the eye caused ischemic damage to retinal tissue, as could be 
documented by morphometric evaluation of the histological 
eye preparations. The representative qualitative picture of the 
changes induced by ischemia in rat retina and the effects of 
NOS inhibitors are shown in Fig. 1. A 75 min ischemic episode 
resulted in a major decrease of the thickness of IRL 7 days after 
the episode (Fig. 1B). Quantitation of the effects of ischemia 
revealed that the thickness of IRL decreased from 110 + 2 ¢tm 
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in untreated controls (injected with vehicle alone, n- -20,  
N = 5) to 49 + 5 pm in ischemic eyes of animals injected with 
vehicle alone (ischemia, n = 20, N = 5, P < 0.001, see Fig. 2A). 
Most of the damage could be attributed to a dramatic decrease 
in the thickness of the IPL. In the same experiment, his struc- 
ture decreased from 49 + 2/,tin (n = 20, N = 5) in untreated 
controls to 5 + 2 pm (n = 20, N = 5, P < 0.001) in ischemic 
eyes, i.e. by approximately 90% (Fig. 2B). In many cases the 
IPL virtually disappeared after ischemia (see Fig. IB). We have 
also observed ischemic damage to the inner nuclear layer, man- 
ifested as disorganization of the cells. 
The IPL is a non-cellular structure. We have, therefore, also 
estimated the number of RGCs, neural cells that do not regen- 
erate after injury in the same experiment. In untreated controls, 
the number of RGCs in the segment measured was 148 + 2 
(n = 40, N = 5). Ischemia resulted in a major (80%) decrease in 
the number of RGCs, to 29 + 2 (n = 40, N = 5, P < 0.001, 
Fig. 3). 
Pretreatment of the animals with a non-selective NOS inhib- 
itor, NNA,  1 h before ischemia resulted in a significant decrease 
in both indices of ischemic damage (P < 0.001). At the optimal 
dose of NNA (25 mg/kg), the IRL was 105 + 7 / lm (97% of 
untreated controls, see Fig. 2A), while the IPL was 43 + 3/ tm 
(88% of untreated controls, Fig. 2B), both values not signifi- 
cantly different from untreated controls (P < 0.05). Similarly, 
the treatment with NNA protected the RGCs from ischemic 
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Fig. 2. Prevention of morphological damage to retina by early admini- 
stration of NNA or AG. Panel A, IRL; panel B, IPL. Drugs were 
injected 1 h before the induction of ischemia. The dose of each drug (in 
mg/kg) is given above the columns. C, untreated, vehicle-injected con- 
trols (n = 20, N= 5); I, ischemic eyes in vehicle-injected animals 
(n = 20, N = 5). Ischemic eyes from NNA- or AG-injected animals: 
NNA 5 mg/kg (n = 8, N = 2); NNA 25 mg/kg (n = 20, N = 5); NNA 50 
mg/kg (n = 24, N = 6), AG 25 mg/kg (n = 20, N = 5); AG 50 mg/kg 
(n=16, N=4). 
Fig. 1. Morphology of the IRL under different experimental conditions. 
(A) Micrograph of a section of a rat retina in control eye taken from 
an animal injected with the vehicle. (B) Ischemic retina from an animal 
injected with vehicle. Note the almost complete disappearance of the 
inner retinal ayer (IPL), few and atypical ganglion cells (RGCs) and 
disorganized inner retinal layer (INL). (C) Ischemic retina from an 
animal injected with 25 mg/kg NNA 1 h before ischemia. Note the 
increase in the thickness of IPL and of INL RGCs are clearly pre- 
served. (D) Ischemic retina from an animal injected with 25 mg/kg AG 
1 h before ischemia. In this eye, AG partially prevented the damage to 
IPL and preserved the number of RGCs. Note: the markings denoting 
the different retinal layers and ganglion cells are shown for control 
retina (panel A) only. 
death, yielding 135 + 4 cells in the segment that was measured 
(91% of untreated controls, P < 0.001, Fig. 3). A lower (5 mg/ 
kg) or a larger dose (50 mg/kg) of NNA had a reduced neuro- 
protective ffect. In many sections, a thickening of the IPL and 
INL was observed, suggesting that the combined effect of is- 
chemia and NNA affected the morphology of the IRL (see Fig. 
1C). 
To assess the role of inducible NOS in ischemic injury, we 
used the more selective NOS inhibitor, AG [10]. Administration 
of 25 mg/kg AG resulted in a variable protection of the retina 
against the ischemic insult. In a number of eyes, a significant 
prevention of ischemic damage to the IPL could be observed 
(see Fig. ID). When the entire experiment was analyzed, a 
much more modest protection was seen. The thickness of the 
IRL was 54 _+ 4t im (49% of untreated controls, n -- 16, N- -  4, 
Fig. 2A), which was not statistically different from ischemic 
eyes (P > 0.05, see above). Similarly, the IPL thickness was 
13 _+ 3pm (n = 16, N - -  4; 27% of untreated controls, Fig. 2B). 
This was significantly different from the ischemic injury alone 
(5 -+ 2 pm, P < 0.02), suggesting that AG offers a limited pro- 
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tection against damage to the IPL. The number of RGCs 
reflected the most significant effect of AG (P < 0.001 when 
compared to ischemic values). We observed 98 + 4 cells in the 
measured segment (n = 32, N = 4), i.e. 66% of untreated con- 
trois. A greater dose of AG (50 mg/kg) was even less effective 
(see Fig. 3). 
In order to evaluate the possible therapeutic effects of drugs 
in clinical situations, it was important to test whether the NOS 
inhibitors used here were effective when administered after 
ischemia. We have tested, therefore, the effects of administra- 
tion of either NNA or AG 1 h after the termination of ischemia. 
The ischemic damage, both when the morphology of the IRL 
and the number of RGCs were assessed, was significantly re- 
duced at lower doses of the drugs, especially when 5 mg/kg 
NNA was tested (Figs. 4AB and Fig. 5). The morphological 
indices were not different from untreated controls and the num- 
ber of RGCs (133 + 4) was significantly (P < 0.005) higher than 
in ischemic eyes. 
4. Discussion 
Nitric oxide, a novel and ubiquitous messenger, has been 
implicated in neuronal injury following anoxia, hypoxia, head 
trauma and a number of neurodegenerative disorders, such as 
Alzheimer's and Parkinson's diseases. A vast body of conflict- 
ing evidence as to the contribution of NO to neuronal cell death 
exists in scientific literature [7]. This is further complicated by 
the existence of constitutive and inducible forms of NOS and 
the various effects of the enzyme's activation on different is- 
sues. Part of the controversy can be explained in terms of 
opposing effects of NO on neuronal cells and on the CNS 
haemodynamics. 
In the present report, we investigated the possible role of NO 
in the ischemic injury to rat retina in vivo, a convenient model 
of neuronal tissue. The retina may serve as a preferential model 
of neuronal tissue ischemic injury for several reasons: (1) is- 
chemic injury can be produced locally by a relatively simple 
procedure; (2) the morphological evaluation of injury is 
straightforward; (3) although the retina, and the eye in general, 
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Fig. 3. Prevention of ischemic damage to RGCs by early administration 
of NNA or AG. Each column represents he number of ganglion cells 
in a part of retina between the equator and the optic disk. C, untreated, 
vehicle-injected controls (n = 40, N = 5); I, ischemic eyes in vehicle- 
injected animals (n = 40, N = 5). Ischemic eyes from NNA- or AG- 
injected animals: NNA 5 mg/kg (n = 16, N= 2); NNA 25 mg/kg 
(n = 40, N = 5); NNA 50 mg/kg (n = 48, N = 6), AG 25 mg/kg (n = 40, 
N= 5); AG 50 mg/kg (n = 32, N = 4). 
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Fig. 4. Protection against morphological retinal damage by late admin- 
istration of NNA or AG. Panel A, IRL; panel B, IPL. Drugs were 
injected 1 h post-ischemia. For other experimental conditions and ab- 
breviations, ee Fig. 2. For NNA (5 or 50 mg/kg) treatment, n = 12, 
N = 3. For AG treatment, n = 8, N = 2 for 25 mg/kg dose; n = 20, N = 5 
for 50 mg/kg dose. 
are not cellularly homogenous and simple structures, their com- 
plexity is much less than that of the central nervous system; 
(4) ischemic injury is implicated in a number of pathological 
states, such as central retinal rtery occlusion, glaucoma, dia- 
betic retinopathy, etc. This makes the study of retinal ischemic 
injury important from the clinical point of view. 
Our results can be summarized as follows: systemic admini- 
stration of NOS inhibitors significantly protected the retina 
from ischemic injury. Although the inner nuclear layer dis- 
played morphological signs of damage, the thickness of the 
non-cellular IPL and the number of RGCs were the most af- 
fected. The latter index is particularly significant, since the 
damage to RGCs is reversible. The protection was most dra- 
matic with relatively low doses of the non-selective NOS inhib- 
itor, NNA. A high dose of NNA (50 mg/kg) was less effective 
than lower doses, a result which is compatible with numerous 
reports attesting to the deleterious effects of reduction of NO 
on neuronal survival, possibly via a decrease in local perfusion 
[4,5]. Aminoguanidine, a selective inhibitor of the inducible 
NOS [10], was much less effective. We propose that NO is 
involved in mediating the ischemic damage in the retina, with 
the possibility hat the constitutive NOS is more important than 
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Fig. 5. Protection against ischemic damage to RGCs by late administra- 
tion of NNA or AG. Drugs were injected 1 h post-ischemia. For other 
experimental conditions andabbreviations, see Fig. 3. For NNA (5 or 
50 mg/kg) treatment, n = 24, N = 3. For AG treatment, n = 16,N -- 2 
for 25 mg/kg dose; n = 40,N = 5 for 50 mg/kg dose. 
the inducible form. Although indirect effects of a systemic ad- 
ministration of NOS inhibitors cannot be excluded, it has been 
shown that NOS is present in the retina [11] and we have 
measured significant concentrations of NO in the vitrous 
(Geyer, unpublished). Furthermore, a recent report on preven- 
tion of retinal ischemia by intravitreal dministration of NNA 
[12] suggests that local NO production may be responsible for 
the ischemic damage. 
Despite the impressive prevention of ischemic damage by 
NNA, there were clear alterations in the morphology of the 
retina in many preparations. These included an increase in the 
thickness of the IPL and the INL. Although we have no expla- 
nation for these changes, they are compatible with either edema 
or hypertrophy of the affected structures. 
Recently, a number of laboratories published conflicting re- 
ports on the function of NO in retinal ischemia in different 
animal models. Protective ffects of NOS inhibitors [12,13], no 
effect [14] and deleterious effect [15] were reported. It is impor- 
tant, however, to emphasize that these reports utilized elec- 
troretinography as an index of ischemic injury, rather than 
morphological parameters. It is noteworthy that NOS inhib- 
itors partially protected also against light-induced photorecep- 
tors degeneration [16]. 
Our preliminary finding that NOS inhibitors afforded signif- 
icant protection against retinal injury when administered post- 
ischemia suggest hat NOS inhibitors, particularly those with 
low systemic toxicity, may be promising agents to limit injury 
in acute pathological situations, uch as retinal artery occlusion 
or chronic conditions, such as glaucoma. Indeed, the morpho- 
logical picture of human retina resulting from these pathologi- 
cal states very closely resembles that of the rat experimental 
model used here [17]. Following central retinal artery occlusion, 
there is a dramatic thinning of inner retinal ayers and a pro- 
nounced loss of ganglion cells. In glaucoma, the predominant 
feature is a major loss of ganglion cells. Hence, although the 
present findings are preliminary, they warrant further esearch, 
particularly in view of the almost complete protection against 
injury by low doses of NNA. 
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